The New Drug Delivery Systems market in North America is expected to grow at a CAGR of 8.7% by 2021.The pharmaceutical industry is changing day by day according to the changing patient requirements and global developments. The need for controlling the pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, biorecognition, and efficacy of drugs has led to the birth of new drug delivery systems.
The industries have diverted their research focus from conventional dosage forms to novel drug delivery technologies with significantly improved market requirements. In recent years, the pharmaceutical companies have been struggling to maintain a balance between the pressure to drop prices and the high innovation costs. It is always advantageous for companies to develop their own innovative delivery devices to maintain a lead in the market.
The US is leading the market in this category with 55 % of the market share in 2010 and is expected to continue the trend during the forecast period. The introduction of novel delivery systems to an existing molecule will significantly improve its safety, efficacy and patient compliance. These factors are bound to significantly affect the North American market for new drug delivery systems.
North America’s NDDS market has been segmented by the mode of delivery and region. By the mode of delivery, the market has been segmented into oral, pulmonary, transdermal and injectable drug delivery systems. These are further segmented by their modes of administration. By region, the market is segmented into the US, Canada and Rest of North America.
Some of the key players in the market are:
What the Report Offers